Hubei Feirui Biopharmaceutical

Hubei Feirui Biopharmaceutical is a clinical-stage biotechnology company based in Wuhan, China, specializing in the discovery and development of innovative small molecule therapeutics. The company primarily focuses on addressing significant unmet medical needs in metabolic diseases and oncology. Its lead candidate, FR-801, is a selective thyroid hormone receptor beta (THR-beta) agonist currently in clinical development for the treatment of non-alcoholic steatohepatitis (NASH). Feirui operates out of the Optics Valley of China, leveraging a robust internal R&D platform to advance a pipeline of targeted inhibitors and agonists. The company aims to deliver high-quality, innovative medicines to patients through its integrated drug discovery and development capabilities.